Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model
Pau Montesinos(Instituto de Salud Carlos III), Miguel Á. Sanz(Instituto de Investigación Sanitaria La Fe), Mariluz Pérez-Sirvent(Hospital Universitari i Politècnic La Fe), Jesús Martı́nez(Hospital Universitari i Politècnic La Fe), Federico Moscardó(Hospital Universitari i Politècnic La Fe), Lorenzo Algarra(Hospital Universitari i Politècnic La Fe), Javier de la Rubia(Universitat de València), Guillermo Ortí(Hospital Universitari i Politècnic La Fe), Jaime Sanz(Hospital Universitari i Politècnic La Fe), Guillermo Sanz(Instituto de Salud Carlos III), Isidro Jarque(Hospital Universitari i Politècnic La Fe), I Di Lorenzo(Hospital Universitari i Politècnic La Fe), Guillermo Martı́n(Hospital Universitari i Politècnic La Fe), David Martínez(Hospital Universitari i Politècnic La Fe)
Cited by 225
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k